retatrutide phase 2 results 2024 2025 Retatrutide—A Game Changer in Obesity Pharmacotherapy Effects of once-weekly subcutaneous retatrutide

Retatrutide's glucagon activity adds small, dose-related increases in heart rate and glucose seen in trials

Many patients find that supportive strategies like proper hydration, gut health support, and working closely with their provider can help manage these effects effectively

The pancreas releases insulin, the hormone that tells the body to absorb glucose (sugar) from the bloodstream

Therefore, by week five of the nine-week weight loss phase, all subjects were on the maximum 30 g/day dose

But the situation has improved significantly, and most patients can now access semaglutide with reasonable wait times

May 2025 GLP-1 FDA policy changes